Breaking Finance News

A statement released earlier today by Zacks Investment Research about Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) bumps the target price to $16.00

Boasting a price of $13.95, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) traded 0.79% higher on the day. With the last stock price close up 67.01% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Ariad Pharmaceuticals, Inc. has recorded a 50-day average of $11.02 and a two hundred day average of $8.42. Volume of trade was down over the average, with 2,989,800 shares of ARIA changing hands under the typical 5,353,590

Zacks Investment Research bumped up the target of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) to $16.00 stating a potential upside of 0.15%.

On 9/26/2016, Leerink Partners released a statement for Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) bumped up the target price from $0.00 to $20.00 that suggested an upside of 0.48%.

Performance Chart

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

With a total market value of $0, Ariad Pharmaceuticals, Inc. has with a one year low of $4.37 and a one year high of $14.26 .

A total of 8 equity analysts have released a ratings update on ARIA. Two equity analysts rating the company a strong buy, one equity analyst rating the company a buy, five equity analysts rating the company a hold, one equity analyst rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $9.00.

Brief Synopsis About Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *